953039-63-9

Basic information

• Product Name: 8-BroMo-2-chloro-6-fluoro-quinazoline
• Synonyms: 8-BroMo-2-chloro-6-fluoro-quinazoline
• CAS NO: 953039-63-9
• Molecular Formula: C₈H₃BrClFN₂
• Molecular Weight: 261.4782232
• Mol File: 953039-63-9.mol

Chemical Properties

• Boiling Point: 308.8±35.0 °C(Predicted)
• Appearance: /Solid
• Density: 1.836
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -1.75±0.30(Predicted)
• CAS DataBase Reference: 8-BroMo-2-chloro-6-fluoro-quinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BroMo-2-chloro-6-fluoro-quinazoline(953039-63-9)
• EPA Substance Registry System: 8-BroMo-2-chloro-6-fluoro-quinazoline(953039-63-9)

Safety Data

• Hazardous Substances Data: 953039-63-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
8-Bromo-2-chloro-6-fluoro-quinazoline is used as a key intermediate in the synthesis of various pharmaceutical compounds for [application reason]. Its unique structure and properties allow for the development of new drugs with potential therapeutic benefits.
Used in Synthetic Chemistry:
In the field of synthetic chemistry, 8-Bromo-2-chloro-6-fluoro-quinazoline is used as a building block for the creation of complex organic molecules. Its specific halogens and nitrogen atoms enable it to participate in a variety of chemical reactions, facilitating the synthesis of novel compounds with potential applications in various industries.
Used in Medicinal Chemistry:
8-Bromo-2-chloro-6-fluoro-quinazoline is employed as a starting material in the design and synthesis of new drug candidates. Its unique structural features make it a promising candidate for the development of targeted therapies and other medicinal agents.
Used in Chemical Reactions of Interest:
Due to its specific structure and properties, 8-Bromo-2-chloro-6-fluoro-quinazoline is used in chemical reactions of considerable interest in both synthetic and medicinal chemistry. Its participation in these reactions can lead to the formation of new compounds with potential applications in various fields.

Upstream product

• 446-08-2 2-amino-5-fluorobenzoic acid 
• 953039-62-8 8-bromo-6-fluoro-quinazolin-2-ol 
• 953039-61-7 2-amino-3-bromo-5-fluorobenzaldehyde 
• 55414-45-4 (2-amino-3-bromo-5-fluorophenyl)methanol 
• 259269-84-6 2-amino-3-bromo-5-fluorobenzoic acid 

Relevant articles and documents

METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS

Provided are methods for expanding stem cells and/or lineage committed progenitor cells, such as hematopoietic stems cells and/or lineage committed progenitor cells, at least in part, by using compounds that antagonize AhR. The compounds are represented by formulae (I) (II) (III) (IV), wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification. Also provided are compositions comprising stem cells and/or lineage committed progenitor cells expanded by methods disclosed herein and methods for the treatment of diseases treatable by same.

AMIDO COMPOUNDS AS AhR MODULATORS

Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification.

CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF

Disclosed are a condensed-ring pyrimidylamino derivative, a preparation method therefor, and an intermediate, a pharmaceutical composition and applications thereof. The method for preparing the condensed-ring pyrimidylamino derivative comprises: in a solvent, in the presence of a palladium-containing catalyst, allowing a compound represented by formula I-a and a compound represented by formula I-b' to have a coupling reaction, and then preparing a compound represented by formula I by means of a deprotection reaction. Also disclosed applications of the condensed-ring pyrimidylamino derivative in the preparation of drugs for preventing, relieving and/or treating tumors or diseases caused by an anaplastic lymphoma kinase. The condensed-ring pyrimidylamino derivative of the present invention has an obvious restraint effect on the anaplastic lymphoma kinase.

FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF

Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

Substituted piperazine compounds, application method and applications thereof

The invention discloses substituted piperazine compounds, an application method and applications thereof. Specifically, the invention relates to piperazine compounds and pharmaceutical compositions thereof for inhibiting reuptake of 5-hydroxytryptamine and/or stimulation of 5-HT1A acceptor. The invention also relates to a preparation method of the compounds and pharmaceutical compositions thereof, and an application of the compounds and pharmaceutical compositions thereof in the treatment of central nervous system dysfunction.

QUINAZOLINES FOR PDK1 INHIBITION

The invention provides novel quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.